Klaria Annual Report 2022

The year in brief

- Net sales amounted to 5.9 MSEK (0.0 MSEK)

- Other operating income amounted to 0.7 MSEK (37.5 MSEK)

- R&D costs amounted to 51.4 MSEK (63.5 MSEK)

- Profit/loss after tax amounted to -63.8 MSEK (-53.5 MSEK)

- Earnings per share amounted to -1.10 SEK (-1.03 SEK)

- Cash flow from operations amounted to -49.7 MSEK (-24.8 MSEK)

- Shareholder’s equity as of December 31, 2022 amounted to 76.1 MSEK (69.4 MSEK)

- Cash and cash equivalents as of December 31, 2022 amounted to 16.8 MSEK (25.5 MSEK)

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.